Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. - Wikidata - awgldk - TriplyDB

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

http://www.wikidata.org/entity/Q34458323

about

Polycomb silencers control cell fate, development and cancer Expression of polycomb group protein EZH2 in nevi and melanoma.Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo.Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.Chromatin Memory in the Development of Human Cancers Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features Connections between epigenetic gene silencing and human disease.Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression Quantitative Assessment of the Polymorphisms in the HOTAIR lncRNA and Cancer Risk: A Meta-Analysis of 8 Case-Control Studies.Cancer genetics of epigenetic genes.Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer.Epigenetic factors in cancer development: polycomb group proteins.EZH2, an epigenetic driver of prostate cancer.Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.Histone modifications: Targeting head and neck cancer stem cells.Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.Polycomb Repressor Complex 2 in Genomic Instability and Cancer Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer.Spatiotemporal expression of Ezh2 in the developing mouse cochlear sensory epithelium.EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer.Targeting the epigenome for treatment of cancer.Effects of four single nucleotide polymorphisms of EZH2 on cancer risk: a systematic review and meta-analysis.NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.[Advances on Driver Mutations of Small Cell Lung Cancer].Epigenetic Mechanisms in Cancer Formation and Progression

P2860

Q29619697-1169C6EF-ABA0-48F8-B40A-68DE8ACD402F Q33291217-2E0F79F9-EC92-43C3-BE2C-CA702522B933 Q34786445-3F051B61-CB72-477D-8BD6-0EFCC2CEF5D4 Q34964303-61080C02-C609-415B-ADF8-011503CA0820 Q34979975-AF768DDD-11B7-4BEF-AE37-EB4EAFA69D32 Q35137483-4A1385F7-F2AA-4DF8-A39D-B6FC10739968 Q35843804-4131096A-175B-4542-BFBA-F03D4BAA4918 Q35849140-27B1D25E-96FA-4330-81FB-0B0D74358742 Q35969025-4E2EBAB9-0571-4526-A79D-7BFD41515D89 Q36871595-9ACB9416-2826-46FF-A5E3-86224389A37D Q37629613-DA8CCC69-058B-4772-945F-0A7E85E58119 Q37822735-75B6FACB-8AAC-41AF-9984-E78E5E784CAC Q38103472-9716BC86-497D-44D5-BE77-4D34022A5473 Q38232172-EAD79F23-FA7F-4D21-B533-EA76F893794B Q38271597-E8108B53-5CFC-4D02-9200-39FAAA958A84 Q40273857-C5B51422-0E0E-4664-9914-059BC2DAE9FA Q41336798-40F4DDC3-F06D-4B3E-B01E-89F60B20FD4A Q41573279-A061C635-8C63-4C7A-8A13-9A8A8D52BE46 Q41918438-D3ADCA66-170B-4E1E-802C-820AECA2B5FB Q42314701-85162A47-D565-4432-A219-3084EEC5A310 Q42496908-A6BFB81D-286E-4EA6-BD21-1B356E774C6B Q48117546-00AD289A-6E45-4371-B99E-D3407BAAF79D Q48200477-776EEFB6-F865-4409-8206-FE51E398C6CE Q53201323-CC69EB4B-52AB-4378-A537-7FA952D63DEE Q53273169-0D5B60CD-1B36-4427-81BB-7E81AD9C994F Q53538138-1A1B521F-0F62-4028-8D1B-601A6C553CA4 Q55011897-D8BAE8B6-81D9-49C1-BE19-3D757C9C9572 Q55464542-BF233597-28D4-41AE-9237-7CD6FD6AFA79 Q57570317-44F390CD-F78F-4332-8E68-5030EC65A862

P2860

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

http://www.wikidata.org/entity/Q34458323

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@ast

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@en

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@nl

type

label

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@ast

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@en

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@nl

prefLabel

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@ast

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@en

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@nl

P1433

Q34458323-C2168180-27E4-49BD-B15E-18D43F4705D0

P1476

Q34458323-FD29D7F5-32BF-4416-BD3D-AA63E170E641

P2093

Q34458323-1C9D9B1E-01DF-4C0D-AD19-EA7F35C2D942

Q34458323-33C19945-EA91-4AB3-897E-DFCB7E80E88B

Q34458323-34F61BC5-1430-4B54-8FF9-29E64EAE1ACD

Q34458323-4DBBD36A-4FF0-4A93-804C-C81F02FAD4E7

Q34458323-A1967CE3-4BC6-4F41-B65C-3F8691177D01

Q34458323-B293B5F9-4090-455C-AAAE-C56FCC2CF527

P2860

Q34458323-14B1E206-FD9F-4A3C-AB8D-58683C2BD29A

Q34458323-4648630F-3857-4697-8CA1-14E49E125C39

Q34458323-6B3119E6-5E78-43BF-A310-A76E667F793D

Q34458323-CBEF023E-36FB-490F-AD05-FE59C90824FC

P304

Q34458323-A08BBC9B-211A-430E-8D43-B185AD1D8615

P31

Q34458323-DB854CF1-5778-4DBF-A580-5C974D9FB6D8

P356

Q34458323-EC6299F9-3777-4571-BDBA-835DA69C12B6

P433

Q34458323-A4554C00-C22D-42D6-B0A2-6B4739A84E93

P478

Q34458323-B7A9B610-2912-46A7-BF9E-B260C0EB5B94

P577

Q34458323-FAECD111-DBE1-4890-A796-C540AF134C04

P698

Q34458323-F835E8AD-9FF1-49D9-942E-BB63C6347857

P356

P1433

Urologia internationalis

P1476

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

@en

P2093

Elif Damla Buyuktuncer

http://www.w3.org/2001/XMLSchema#string

Erbil Ergenekon

http://www.w3.org/2001/XMLSchema#string

Narcin Palavan-Unsal

http://www.w3.org/2001/XMLSchema#string

Omer Onur Cakir

http://www.w3.org/2001/XMLSchema#string

Serdar Arisan

http://www.w3.org/2001/XMLSchema#string

Turhan Caşkurlu

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes.

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.

Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.

P304

252-257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000087804

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16215315

http://www.w3.org/2001/XMLSchema#string